Vorapaxar Woes Increase Pressure On Remainder Of Merck CV Pipeline
Executive Summary
The mid-January announcement that Merck & Co. was ending one pivotal trial and removing patients with a history of stroke from another for Phase III anti-clotting agent vorapaxar has called into question the pharma’s continued heavy emphasis on cardiovascular research and development.
You may also be interested in...
For Merck, Outcomes Trials Offer Fast Track To Payers
More so than any other big pharma, Merck is dependent on large outcomes trials. The cost of failure is high, but success would allow entry into massive, highly generic primary care markets with products backed by clinical outcomes data that meet payers’ need for real-world evidence of a drug’s value in terms of health economics as well as clinical efficacy.
Back To The Drawing Board For Portola After Merck Returns Betrixaban
Merck & Co. returned the Phase III-ready oral Factor Xa inhibitor; Portola spins the news as an opportunity, but finding a new partner may be challenging.
Back To The Drawing Board For Portola After Merck Returns Betrixaban
Merck & Co. returned the Phase III-ready oral Factor Xa inhibitor; Portola spins the news as an opportunity, but finding a new partner may be challenging.